ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
ESMO2016 Eye on ESMO: Day Three - Merck & Co. wins big lung cancer ba... Merck unveils impressive data on Keytruda, trumping BMS' Opdivo
ESMO2016 Cancer market commentary: 3 highlights from ESMO (Part 1) Commentary on key cancer data from ESMO by Stephanie Hawthorne
ESMO2016 Eye on ESMO: Day 2 - gamechangers take centre stage Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
ESMO2016 Eye on ESMO: Day 1 - Access in spotlight before data deluge Europe's biggest cancer conference ESMO is underway
News After internal setbacks, Pfizer buys obesity player Metsera Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
